InterCure Ltd. (INCR) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of InterCure Ltd. $2.38, price $5.42, upside -56.1%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch InterCure Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range $3.65 – $43.30 · fair‑value band $1.42 – $4.26 · the $5.42 price screens above the $2.38 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow InterCure in your weekly email
Every Wednesday you see whether InterCure is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector.
Show more
InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Stock analysis
InterCure Ltd. (INCR) currently trades at $5.42, while our model-based Fair Value estimate is $2.38, 56.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $2.68 per share, and 0 of the 13 models we run sit above the $5.42 price.
Bear case: the Multiples group reads lowest at $0.5800, and 13 of the 13 models stay below the price. Evidence for this calculation is low.
Scenario range: $1.42 (bear) to $4.26 (bull), the price of $5.42 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
InterCure Ltd. reported revenue of 270M ILS in FY2025 versus 220M ILS in FY2021, a compound +5.3%/yr. Reported net income was −35.7M ILS in FY2025.
Key figures
Market cap $53.1M · P/S ratio 0.22 · EPS (TTM) $−0.2300 · Net margin −13.2% · Return on equity −9.3% · Return on assets (EBIT) −0.7% · Revenue (TTM) 243M ILS · Revenue growth (YoY) +23.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 35% below its 52-week high and 48% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −56%, INCR screens richer than that median.
Fair Value models
Bear $1.42Fair Value $2.38Bull $4.26
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+13.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.0%
Start year 2020 (pandemic). Over 10 years: +69.2% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.3%
’11
’12
’13
’14
’15
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−38.3% (2019) → −28.1% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+41.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in ILS, Israel: IMF forecast 2.1% a year to 2030, 1.7% from 2016 to 2025) that is about +38.5% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks
Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score40 · Bottom 25%
Fair Value upside−55.7% · Below median
Profitability
Return on assets−5.8% · Bottom 25%
Net margin (TTM)−13.2% · Bottom 25%
Operating margin (TTM)0.0% · Below median
Growth and dividend
Revenue growth23.9% · Top 25%
Balance sheet
Debt / equity0.15× · Above median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 17
FUTURE (revenue growth)100· sector 24
PAST (return on equity)0· sector 27
HEALTH (low debt)93· sector 96
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "InterCure Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/INCR
Frequently asked questions
Is InterCure Ltd. (INCR) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $2.38 versus a price of $5.42, about −56% upside (overvalued).
What is the fair value of INCR?
Our model-based fair value for InterCure Ltd. is $2.38 (as of Sep 27, 2026), built from audited fundamentals. The current price: $5.42.
What is the quality score of INCR?
InterCure Ltd. has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for InterCure Ltd. (INCR)?
Our model-based price target is the fair value of $2.38 (as of Sep 27, 2026) from 13 valuation models. Cautious scenario $1.42, optimistic scenario $4.26. It is a calculation from audited fundamentals, not an analyst target.
What is the InterCure Ltd. stock forecast for 2026?
Our models put fair value at $2.38, about −56% upside versus a price of $5.42 (overvalued). Cautious scenario $1.42, optimistic scenario $4.26. The calculation is refreshed regularly with new filings.
What is the revenue of InterCure Ltd. (INCR)?
InterCure Ltd. reported trailing-twelve-month revenue of about 243M ILS (latest available figure, as of Sep 27, 2026).
What growth is priced into InterCure Ltd. (INCR)?
For today's price to be fair in a discounted-cash-flow model, InterCure Ltd. would have to grow free cash flow by +41.4 % per year for five years (discount rate 11.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +33.0 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of INCR use?
Our models discount InterCure Ltd. at 11.4 %: a base by market capitalisation (micro), damped by beta 0.57, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For InterCure Ltd. that is +41.4 % per year a year over ten years, using the same discount rate (11.4 %) and the same formula as our fair value.
How much growth has InterCure Ltd. (INCR) delivered so far?
Over the past 5 years revenue at InterCure Ltd. grew +33.0 % a year. The price currently implies +41.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of InterCure Ltd. (INCR) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into InterCure Ltd. (+41.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of InterCure Ltd. (INCR)?
The free-cash-flow yield on the price is 1.41 %: that much free cash flow InterCure Ltd. produces per unit of market value. When it exceeds the discount rate of our models (11.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of InterCure Ltd. (INCR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For InterCure Ltd. it is $2.38 per share (as of Sep 27, 2026), against a price of $5.42. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is InterCure Ltd. stock overvalued or undervalued in 2026?
As of Sep 27, 2026, INCR trades above its calculated fair value: price $5.42, fair value $2.38, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of INCR?
No. The price is what the market pays today ($5.42); the fair value is what the company's own numbers justify ($2.38). For InterCure Ltd. the two are $3.04 per share apart. That gap is exactly why we show both numbers side by side.
How much is InterCure Ltd. worth?
The market values InterCure Ltd. at about $53.1M (market capitalisation, as of Sep 27, 2026). Per share that is $5.42; our models calculate a fair value of $2.38 per share.
What do the bullish and bearish scenarios say about INCR?
Our models span a range for InterCure Ltd.: cautious scenario $1.42, base $2.38, optimistic $4.26 per share (as of Sep 27, 2026, price $5.42). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of InterCure Ltd. (INCR)?
Balance-sheet figures for InterCure Ltd. (as of Sep 27, 2026): return on equity −9.3%, debt of 0.15 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is INCR from its 52-week high?
InterCure Ltd. trades at $5.42, about 35% below its 52-week high of $8.40 and 48% above the low of $3.65 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $2.38 is for.
Which stocks are comparable to InterCure Ltd.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is InterCure Ltd. stock attractive at the current price?
The data as of Sep 27, 2026: price $5.42, calculated fair value $2.38 (−56%), Quality Score 40/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of INCR calculated?
We run InterCure Ltd. through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $2.38, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. InterCure Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of InterCure Ltd. (INCR)?
The closing price on Oct 2, 2026 was $5.42. Our model-based fair value is $2.38, about −56% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with InterCure Ltd. right now?
The price sits above even our optimistic bull case ($4.26). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide ($1.42 to $4.26). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of InterCure Ltd.
How large is the market capitalisation of InterCure Ltd. (INCR)?
The market capitalisation of InterCure Ltd. is $53.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of InterCure Ltd. (INCR)?
The price-to-sales ratio of InterCure Ltd. is 0.22 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of InterCure Ltd. (INCR)?
Earnings per share at InterCure Ltd. are $−0.2300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of InterCure Ltd. (INCR)?
The net margin of InterCure Ltd. is −13.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of InterCure Ltd. (INCR)?
The return on equity (ROE) of InterCure Ltd. is −9.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of InterCure Ltd. (INCR)?
On an EBIT basis the return on assets of InterCure Ltd. is −0.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at InterCure Ltd. (INCR)?
Revenue at InterCure Ltd. is growing +23.9% versus a year earlier (3y avg −11.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at InterCure Ltd. (INCR)?
Earnings per share at InterCure Ltd. are growing −84.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does InterCure Ltd. (INCR) carry?
The net debt of InterCure Ltd. is 137M ILS (fiscal year 2025, ≈ 10.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch InterCure Ltd. in the live analysis
One click puts InterCure Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026